Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: J Neurovirol. 2018 Apr 24;24(4):498–505. doi: 10.1007/s13365-018-0642-4

Table 2.

CSF GTR results

Plasma HIV RNA CSF HIV RNA PI SDRM RT SDRM Resistance Previous ART
47/M (JM) 185 copies/ml 3650 None D67N, M184IV V179D HL: 3TC, FTC LL: ABC, EFV, NVP, RPV, ETR Naïve
44/M (MS) 3040 84,300 M46I, N88S M l84V HL ATV, 3TC, FTC LL: LPV/r, ABC TDF/3TC/EFV
45/M (JG) 919 20,000 L231, G73S, L89V M41 L, V106M, M184V, T215Y, M230L HL: 3TC, FTC, NVP, EFV, RPV LL: ATV, ABC, AZT, TDF, ETR AZT/3TC/NVP
37/F (VM) 1270 24,700 M46I, V82A, L90M D67N, T69D, K70R, K101E, Y181C, Ml 84V, K219Q HL: ATV, LPV/r, 3TC, FTC, NVP, RPV LL: AZT, TDF, EFV, ETR AZT/3TC/NVP
46/M (KP) 6400 57,600 None M184V HL: 3TC, FTC d4T/3TC/NVP

HL high level, LL low level, NVP nevirapine, EFV efavirenz, ABC abacavir, 3TC lamivudine, FTC emtricitabine, ATV atazanavir, LPV/r lopinavir/ritonavir, TDF tenofovir disoproxil fumarate, RPV rilpivirine, AZT zidovudine, ETR etravirine